The Ophthalmic Pharmaceutical Market Outlook to 2016Business InsightsSeptember 16, 2011 7 Pages - SKU: RET6647616 |
| This report provides comprehensive coverage of the global ophthalmic market, incorporating disease overviews, epidemiological analyses of the major indications, and market dynamics. Five forces analysis underlines the prevailing industry dynamics. Current leading ophthalmic brands within each drug class are assessed and five leading and three emerging players are profiled. Identify changing epidemiologies to 2016 of glaucoma, AMD and dry eye syndrome in the US, 5EU and Japan. Analyze the dynamics of the global ophthalmic market and understand the impact of key R&D events, market trends, and issues. Understand how recent events are affecting the performance of major products and how their marketers are confronting competitive challenges. Evaluate the product pipelines of the leading players in the ophthalmic market and determine which of them are best positioned for future success. Develop strategies for success in the future ophthalmic market. Glaucoma is the largest segment within the ophthalmic market, with sales of $5.6bn in 2010, which will grow at a CAGR of 2.5% to 2016. Xalatan sales are eroding in the US since its patent expiry in March 2011. If an EU pediatric extension is granted the brand will remain protected until January 2012. Increased use of contact lenses and computers has led to increase dry eye syndrome (DES) in younger age groups. Despite this artificial tear market is expected to be static to 2016. The retinal disease segment which includes age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and retinal vein occlusion (RVO) was valued at $3.5bn in 2010, and will be the fastest growing area with a CAGR of 14.1% to 2016. What will be the major growth indications and the accompanying growth drivers in the ophthalmic pharmaceutical market between 2010 and 2016? What market and pipeline developments are shaping the strategies of leading players in the ophthalmic market? What is the forecast market size and growth rate of the ophthalmic pharmaceutical market over the period 2010-16? Who were the leading players in the global ophthalmic market in 2010 and what were their market shares? What are the current trends in the diagnosis, treatment and epidemiology of key ophthalmic indications including glaucoma, dry eye and AMD? Please note: this is delivered as a Zip file. |
Related Markets
Ophthalmology Reports
- Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H1, 2012
- Cataract Global Clinical Trials Review, H1, 2012
- 3rd World Congress on Controversies in Ophthalmology 2012 - Post-Conference Review and Analysis
- Diarrhea Global Clinical Trials Review, H1, 2012
- Ophthalmic Drugs: World Market Prospects 2012-2022
